The U.S. Food and Drug Administration (FDA) has approved a new flu vaccine for older adults made using Moderna’s mRNA technology. Multiple outlets describe it as the first flu shot built on the same type of mRNA platform used for COVID-19 vaccines that helped drive the pandemic response. The approval is intended to provide an mRNA-based option for people in an older age group who are generally at higher risk of complications from seasonal influenza. The reporting focuses on the significance of using mRNA for flu prevention, noting that mRNA technology has already been established through COVID-19 vaccine development and deployment. Details beyond the approval and intended audience are not included in the provided excerpts, but both sources frame the FDA decision as a step toward broader use of mRNA approaches for seasonal respiratory viruses. Overall, the articles agree that the FDA authorization covers a Moderna-developed mRNA-based flu vaccine specifically for older people.
FDA approves Moderna mRNA-based flu vaccine for older adults
The U.S. Food and Drug Administration (FDA) has approved a new flu vaccine for older adults made using Moderna’s mRNA technology. Multiple outlets describe it as the first flu shot built on the same t...
- The FDA approves a Moderna-developed mRNA-based flu vaccine.
- The vaccine is intended for older adults.
- It is described as the first flu shot using mRNA technology similar to COVID-19 vaccines.
- Both outlets link the approval to the broader track record of mRNA vaccines used during the COVID-19 pandemic.
The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic
2 hours ago
TikTok creator Sydney Towle dies at 26 after battle with cholangiocarcinoma
Sydney Towle, a TikTok creator with more than 1.1 million followers, dies at age 26 after a prolonged battle with a rare...
Glanbia raises full-year forecasts on protein demand and stronger first-half performance
Glanbia says it is increasing its full-year earnings forecast after reporting a strong first half and citing continued m...
FDA approves Moderna’s first mRNA seasonal flu vaccine for adults 50 and older
The U.S. Food and Drug Administration (FDA) approves mFlusiva (mRNA flu vaccine), the first licensed influenza shot made...